Roche regards lasting innovation as the company’s most important contribution to society

Our vision is to work towards truly personalised medicine, where every patient receives individualised treatment to improve their health outcomes. By embracing the most advanced technology and utilising our invaluable partnerships, Roche harnesses the power of our unique network to advance and develop new therapies and diagnostic tests.

Our ongoing innovation covers many different areas including oncology, neuroscience, inflammation, immunology, ophthalmology, rare diseases, cardiovascular disease, respiratory diseases and diabetes.

Driving Digital Diagnostics

Accelerating and improving individualised treatment options for cancer and critical care patients through the development of digital clinical decision-making solutions is at the core of our strategic, long term partnership with GE Healthcare.

Real-World Health Analytics

Roche subsidiary, Flatiron Health, is driving personalised healthcare and pioneering the curation and development of real-world evidence in cancer research thanks to our leadership in data analytics.

Remote Patient Monitor

Roche is investigating innovative smartphone-based self-monitor technology to gain greater insights into multiple sclerosis (MS). Our new global study, FLOODLIGHT Open, will monitoring disease activity and disability progression over the whole 365 days in a year that someone lives with MS, versus just the two or three days a year they may visit their neurologist. FLOODLIGHT will open in Australia in 2019.

Piloting tele-trials in Australia

Roche is piloting a number of tele-trials in Australia, including one for lung cancer. The tele-trial model uses tele-health to enable clinicians from larger centres (primary sites) to enrol, consent and treat patients on clinical trials at regional and rural centres (satellite sites).

What we are working on

Discover more

please be aware that you are leaving this website.